1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > ACADEMIA
ACADEMIA
- 865,238 People Diagnosed with Cancer in 2012: NCC
June 30, 2016
- MHLW Study Group Aims to Formulate Guidelines for Treatment of Skeletal Dysplasias in FY2017
June 29, 2016
- Nexium, Takecab Added to Standard Treatments for 1st Eradication of H. Pylori: JSHR Guidelines
June 28, 2016
- PD-1’s “Actual Physiology Remains Unclear”: Discoverer of PD-1
June 21, 2016
- No Increased Mortality Risks Seen in Japanese AD Patients on Antipsychotics: Study
June 17, 2016
- Victoza 1st GLP-1 Agent to Thwart Cardiovascular Events; Will It Catch on?
June 15, 2016
- Academic Societies Drafting Guidelines for Clinically Evaluating Efficacy of Drugs for AMR Infectious Diseases
June 15, 2016
- As Spate of Melanoma Drugs Debut, Physicians Still Exploring Best Drug Choices, Combos
June 14, 2016
- Gilead’s 2 Hep C Treatments Highly Effective in Actual Clinical Practice: Multicenter Studies Results
May 24, 2016
- Diabetes Society Calls for Careful Administration of SGLT-2 Inhibitors to Geriatric Syndrome Patients, Aged 75 or Over
May 19, 2016
- MHLW Study Group Drafting Guidelines for Assessing Cost-Effectiveness of Vaccines Proposed for Inclusion in Public Vaccination Programs
May 16, 2016
- Use Patient Registries for Orphan, Intractable Diseases First: MHLW Study Group Chief
May 9, 2016
- At Least 20% of Patients Taking Xeljanz against Guidelines: Interim Analysis of PMS
April 26, 2016
- AMED Study Team Drafting First Guidelines for Diagnosis and Treatment of Post-Stroke Epilepsy
April 21, 2016
- 17 Japanese Medical Societies Jointly Recommend HPV Vaccines
April 20, 2016
- Positioning of Abraxane and Anti-PD-1 Antibodies Will Be Focus of Interest in Revised Guidelines for Gastric Cancer
March 23, 2016
- It’s Time to Discuss Restart of HPV Vaccine Promotion, Panel Chief Says as Personal View
March 16, 2016
- Biomarkers Urgently Needed to Tackle Ballooning Immunotherapy Costs: Oncologist
March 15, 2016
- Japan’s First Diabetes Management Guidelines for Elderly to Be Announced in May
March 11, 2016
- Development of AT2 Receptor-Related New Drugs Forging Ahead Overseas, but Japan Is “Far Behind”
February 22, 2016
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…